Price movement over the last 24 hours
Alcon AG vs Health Care Select Sector SPDR Fund — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while Health Care Select Sector SPDR Fund trades at $163.09. The key difference: Alcon AG pays a 0.54% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | XLV | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | — |
52-Week High | $92.22 | $164.48 |
52-Week Low | $62.02 | $129.01 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
XLV trades at $162.06, down 1.03% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The healthcare ETF benefits from defensive sector positioning amid market volatility, with recent news highlighting healthcare as a safe haven during choppy markets. A dividend of $0.66 is scheduled for June 2026, providing income appeal.
Outlook remains positive given healthcare's defensive characteristics and innovation momentum in biotech and pharmaceuticals. Key risks include sector-specific regulatory pressures and patent cliff concerns for major holdings. Analyst sentiment leans bullish with technical support at $160 and resistance at $164.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →